Study of immune-based biomarkers using the longitudinal CLIMB dataset
Abstract
During this period, we have evaluated proteomic biomarkers and their associations with relapses and/or new gadolinium enhancing lesions (GD+) and 10-year outcomes in MS patients. We have specifically identified that serum neurofilament light chain (sNFL) is elevated within a 3-month window of new GD+ MRI lesions, which informs the frequency at which this biomarker may be surveyed in the clinical setting. We have also found that at a relapse or GD+ lesion that sNFL decreases with increasing age, with the opposite in remission samples. We have screened over 1100 other proteins and have identified a multivariate proteomic signature that more strongly associates with GD+ lesions than serum NFL alone. We have found that serum NFL levels within the first 3-5 years after disease onset strongly correlate with 10-year brain atrophy and deep grey matter volumes including thalamic volumes. These findings can inform the uses of sNFL and a multivariate proteomic biomarker in clinical MS settings.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1125009
Entities
People
- Tanuja Chitnis
Organizations
- Brigham and Women's Hospital